HIV itself doesn’t raise the risk of getting the new virus, but some HIV-positive people are prone to severe illness.

A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.

Merck’s investigational antiretroviral is a reverse transcriptase¬ translocation inhibitor.

Black queer men of MOBI talk about it all—including OnlyFans, HIV and adult films—in this artful digital video series.

The CDC has issued a report detailing considerations for clinicians prescribing PrEP for this population.

A closer look at New York State’s ETE metrics and the progress made since 2014.

A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections

Researchers broke down PrEP use and HIV diagnosis data by state to analyze connections between them.

A survey of local health departments reveals concerning news—and a silver lining.